Mayo Clinic CEO: Regulation hinders advancement of telemedicine

| | Health Exec | Precision Medicine

When the leader of a world's largest healthcare providers in the world has something to say, people tend to take notice. John Noseworthy, MD, president and CEO of Rochester, Minnesota-based Mayo Clinic, recent penned an op-ed in the Twin Cities Pioneer Press that called for regulatory advancements in the field of telemedicine. According to him, the potential of the technology is not being realized because of obstacles from outdated regulations.

"Failure to update the telemedicine regulations contradicts the growing evidence that telemedicine increases patients’ access to health care and reduces overall health care spending for the government," he wrote. "Telemedicine offers significant potential to improve patient access while reducing costs. Telemedicine delivers the right care, at the right time and in the right place—whether that place is a patient’s home or a distant clinic facility without sub-specialty care resources. The need for this sophisticated technology is not limited by geographical boundaries."

For the full op-ed, clink of the link below:

John Noseworthy: Telemedicine will increase access to care, reduce costs

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Cardiovascular Business
Cardiology groups cheer new bill that would improve access to Medicare claims data

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup